Skip to content
Use caution Drug recall · FDA · Published August 23, 2012

Novarel Recall: Missing Anaphylaxis Warning on Label

Ferring Pharmaceuticals recalls Novarel (NDC 55566-1501-1) due to missing anaphylaxis warnings in the package insert. Check your lot numbers.

🇺🇸 FDA recall #D-073-2013DrugNovarel ›
Take action

Contact the company

Recalling firmFerring Pharmaceuticals Inc4 Gatehall Dr Fl 3rd · Parsippany, NJ 07054-4518
✎ GovInfoNow plain-language explainer

What happened, in plain English

Ferring Pharmaceuticals Inc is recalling specific lots of Novarel, a chorionic gonadotropin injection used for intramuscular administration. The recall addresses a labeling defect where the package insert fails to include a required warning that anaphylaxis has been reported with urinary-derived hCG products. Because the remedy is not stated in this record, consumers should contact their healthcare provider for guidance on how to proceed. Read more at govinfonow.com/recall/48592-ferring-pharmaceuticals-inc-recalls-novarel-chorionic-gonadotropin-for-injection-usp.

Source Summary by GovInfoNow · govinfonow.com/recall/48592-ferring-pharmaceuticals-inc-recalls-novarel-chorionic-gonadotropin-for-injection-usp · Updated October 13, 2026 · FDA enforcement record: FDA #D-073-2013

Cite this page

“Novarel Recall: Missing Anaphylaxis Warning on Label.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48592-ferring-pharmaceuticals-inc-recalls-novarel-chorionic-gonadotropin-for-injection-usp. Based on FDA recall #D-073-2013 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-073-2013%22&limit=1).

Why it’s dangerous

The missing warning statement means patients and healthcare providers may not be alerted to the potential for anaphylaxis, a severe allergic reaction, when using this urinary-derived hCG product. Without this information, individuals might not recognize or prepare for this serious side effect during normal use.

Who’s affected

Patients prescribed Novarel for fertility treatments who have received lots manufactured by DRAXIS Specialty Pharmaceuticals Inc. between 2012 and early 2013 are at risk of being unaware of the anaphylaxis warning.

How to tell if you have this one

Check your Novarel carton for NDC # 55566-1501-1 and verify the lot number against the following list: 1C264A (Exp 09/12), 1H047A (Exp 12/12), 1H047B (Exp 12/12), 1H052A (Exp 12/12), 1H052B (Exp 04/13), 1H052C (Exp 04/13), 1M417A (Exp 04/13), 1M417B (Exp 09/13), 2A012A (Exp 09/13), 2A012B (Exp 11/13), 2C278A (Exp 09/13), 2C278B (Exp 09/13), 2C278C (Exp 11/13), 2C278D (Exp 11/13), or 2C278E (Exp 11/13).

  • Brand
    Novarel
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Your Lot Number

    Compare the lot number on your Novarel carton against the recalled list provided in the record to see if your product is affected.

  2. Contact Healthcare Provider

    Speak with your doctor or pharmacist immediately, as the specific remedy for this recall is not stated in the official record.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 21 months after the firm started it.

1. Firm started the recall: Aug 23, 201212. FDA classified it Class III: Nov 30, 201223. Published in FDA’s Enforcement Report: Dec 12, 201234. FDA terminated the recall: May 30, 2014420122014
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

What is the specific NDC number for the recalled product?

The recalled item is identified by NDC # 55566-1501-1, which is displayed on the unit of sale (carton containing 1 vial of NOVAREL and 1 vial of diluent).

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-073-2013 (August 23, 2012) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-073-2013 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA